Alexion Pharmaceuticals (ALXN) : Tuesdays money flow analysis of Alexion Pharmaceuticals (ALXN) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $155.37 million. In comparison, the inflow of money on upticks was a meager $49.52 million. The dollar value of composite uptick trades minus the downtick trades was negative $105.84 million. The uptick to downtick ratio of 0.32 in the money flow shows weakness. The uptick block trades were valued at $12.5 million. The downtick transaction value was high at $115.56 million, which denotes distribution on strength. The uptick to downtick ratio of block trades was 0.11. Hence, the net money flow in the stock was negative ($103.06 million). Alexion Pharmaceuticals (ALXN) gained $0.05 at $125.35, a change of 0.04% over the previous days close.
The company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.86% . Institutional Investors own 98.92% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -2.23%. In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, Moriarty John B had sold 918 shares worth of $124,591 in a transaction dated June 13, 2016. In this transaction, 918 shares were sold at $135.72 per share.
Shares of Alexion Pharmaceuticals, Inc. appreciated by 6.55% during the last five trading days but lost 7.57% on a 4-week basis. Alexion Pharmaceuticals, Inc. has dropped 18.37% during the last 3-month period . Year-to-Date the stock performance stands at -34.29%.
Alexion Pharmaceuticals (NASDAQ:ALXN): stock turned positive on Tuesday. Though the stock opened at $125.98, the bulls momentum made the stock top out at $127.2 level for the day. The stock recorded a low of $124.22 and closed the trading day at $125.35, in the green by 0.04%. The total traded volume for the day was 2,413,377. The stock had closed at $125.3 in the previous days trading.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.